Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
Part 1: What is hepatitis C and how is it diagnosed?
New WHO guideline on care and treatment of chronic hepatitis C
Generic daclatasvir (60 mg) availability and India market pricing as of 30 January 2016
Strategies to Secure Access to Generic HCV Medicines
Four Indian generic companies take sub license from MPP on daclatasvir
Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
Patient Groups and CSOs in Asia written a letter to Indian Government to Request Waiver on Local Clinical Trial for The Coming Generic DAAs
Updated Patent Situation on Key Products for Hepatitis C Treatment in Asia – August 2015
